Catabasis Pharma (CATB) Tops Q1 EPS by 4c

Catabasis Pharma (NASDAQ: CATB) reported Q1 EPS of ($0.41), $0.04 better than the analyst estimate of ($0.45).

As of March 31, 2017, Catabasis had cash and cash equivalents of $31.8 million, compared to $38.5 million in cash, cash equivalents and available-for-sale securities as of December 31, 2016. Catabasis expects that its current cash and cash equivalents as of April 30, 2017, will fund operating expenses, debt service and capital expenditure requirements based on its current operating plan for at least 12 months from today. Net cash used in operating activities for the three months ended March 31, 2017 was $8.1 million, compared to $9.1 million for the three months ended March 31, 2016.

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Amprius Technologies, Inc. (AMPX) Reports In-Line Q1 EPS; offers guidance
• Alphatec Holdings (ATEC) Reports In-Line Q2 EPS ; Offers Guidance
• ICL (ICL) Tops Q2 EPS by 1c